Telacebec, a Potent Agent in the Fight against Tuberculosis: Findings from a Randomized, Phase 2 Clinical Trial and Beyond

Journal:
American Journal of Respiratory and Critical Care Medicine
Published:
DOI:
10.1164/rccm.202408-1632oc
Affiliations:
5
Authors:
11
Go to article
Institutions Authors Share
Qurient Co., South Korea
5.000000
 0.45
TASK, South Africa
2.500000
 0.23
Radboud University Medical Centre (Radboudumc), RU, Netherlands
1.500000
 0.14
University of Cape Town (UCT), South Africa
1.000000
 0.09
TB Alliance, United States of America (USA)
1.000000
 0.09
Interested in Clinical Sciences?